Publications by authors named "Zach Bredl"
J Manag Care Spec Pharm
July 2022
Article Synopsis
- ATTR-CM is a serious heart condition typically seen in older adults, and the drug tafamidis is the first approved treatment since May 2019, shown to have high adherence rates in clinical trials.
- A study was conducted using Medicare claims data to examine how well patients adhered to their tafamidis prescriptions in the real world, along with their demographics and concurrent medications.
- Out of 3,558 patients evaluated, most were over 65, with significant percentages aged 75 to 84, indicating that the patient population reflects known demographics of those affected by ATTR-CM.
